Bone Marrow CD34+/lin− Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) After 12 Months of Nilotinib Treatment Exhibit a Different Gene Expression Signature Compared to the Diagnosis and the Corresponding Cells from Healthy Subjects
Simple Summary: Nilotinib and other tyrosine kinase inhibitors (TKIs) target the BCR-ABL1 oncoprotein in Chronic Myeloid Leukemia (CML), reducing the growth of leukemic stem cells (LSCs) and promoting their death. However, some LSCs persist in the bone marrow (BM), which may lead to relapse and dise...
| Publicado en: | Cancers Vol. 17; no. 6; pp. 1022 - 1036 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
MDPI
Mar2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=184104579&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 184104579 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 20726694 B74B jtl: Cancers issn: 20726694 maglogo: N pubinfo: dt: Mar2025 vid: 17 iid: 6 pid: 97109 pub: MDPI artinfo: ui: 184104579 184104579 184104579 10.3390/cancers17061022 184104579 ppf: 1022 ppct: 14 formats: tig: atl: Bone Marrow CD34+/lin− Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) After 12 Months of Nilotinib Treatment Exhibit a Different Gene Expression Signature Compared to the Diagnosis and the Corresponding Cells from Healthy Subjects aug: au: Trojani, Alessandra Pungolino, Ester Di Camillo, Barbara Bossi, Luca Emanuele Palumbo, Cassandra D'adda, Mariella Perego, Alessandra Turrini, Mauro Elena, Chiara Borin, Lorenza Maria Iurlo, Alessandra Malato, Simona Spina, Francesco Latargia, Maria Luisa Spedini, Pierangelo Artale, Salvatore Anghilieri, Michela Carraro, Maria Cristina Bucelli, Cristina Beghini, Alessandro affil: Department of Hematology and Oncology, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy sug: subj: Gene Expression Profiling Bone Marrow Physiopathology Antigens, Surface Analysis Leukemia, Myeloid, Chronic Drug Therapy Nilotinib Therapeutic Use Human Leukemia, Myeloid, Chronic Diagnosis Signal Transduction Physiology Genes Evaluation Stem Cells Drug Effects Stem Cells Physiopathology Protein Kinases Drug Effects Recurrence Risk Factors Transplant Donors ab: Simple Summary: Nilotinib and other tyrosine kinase inhibitors (TKIs) target the BCR-ABL1 oncoprotein in Chronic Myeloid Leukemia (CML), reducing the growth of leukemic stem cells (LSCs) and promoting their death. However, some LSCs persist in the bone marrow (BM), which may lead to relapse and disease progression. We analyzed the gene expression profiling of BM CD34+/lin− cells from 79 Chronic-Phase CML patients at diagnosis and after 12 months of nilotinib treatment, comparing them to the healthy cells from 10 donors (CTRLs). Our study identified key genes involved in eight crucial biological pathways: CML, cell cycle, JAK-STAT, PI3K-Akt, MAPK, Ras, NF-kB, and ABC transporters. We observed a progressive down-regulation of the expression levels of several genes across these pathways from diagnosis to 12 months of nilotinib treatment and to CTRLs. This could suggest that nilotinib effects create selective pressure, potentially supporting the survival and self-renewal of LSCs. Background: Chronic-Phase Chronic Myeloid Leukemia (C-PCML) is defined by the presence of the BCR-ABL1 fusion gene, which encodes a tyrosine kinase protein that drives the uncontrolled proliferation and survival of leukemic stem cells (LSCs). Nilotinib, a tyrosine kinase inhibitor, targets the activity of BCR-ABL1 by reducing aberrant signaling pathways, which drive the regeneration of LSCs. Despite nilotinib's action, a population of resilient LSCs persist in the bone marrow (BM) and can indeed drive relapse and progression in CML patients. Methods: Our study investigated the gene expression profiling (GEP) of BM CD34+/lin− cells from 79 CP-CML patients at diagnosis, compared to the BM CD34+/lin− cells from the same patients after 12 months of nilotinib treatment and to the normal counterpart cells from 10 donors (CTRLs). Results: GEP analyses identified 3012 significantly differentially expressed genes across these comparisons. Among these, we focused on certain key genes associated with eight crucial KEGG pathways: CML, cell cycle, JAK-STAT, PI3K-Akt, MAPK, Ras, NF-kB, and ABC transporters. Within these pathways, we observed the up-regulation of several genes at diagnosis compared to both 12 months of nilotinib treatment and the CTRLs. Conclusions: We observed that certain transcriptome features present at diagnosis persisted after 12 months of nilotinib treatment, compared to CTRLs. This suggests that nilotinib may exert selective pressure, potentially supporting the survival and self-renewal of LSCs. Future insights into these pathways could help identify therapeutic targets to improve outcomes in CML. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|